Normosang (Human Hemin)

Human Hemin supplies exogenous heme, which restores the normal negative feedback on the enzyme aminolevulinic acid synthase (ALAS1) in the liver. This feedback suppresses the over‑production of aminolevulinic acid and porphobilinogen, the toxic intermediates that trigger acute porphyria attacks, thereby stabilizing the heme biosynthetic pathway.

The dose of Normosang is determined by the prescribing clinician based on the severity of the porphyria attack, the patient’s weight, renal and hepatic function, and response to prior therapy. Dosing regimens are individualized and should follow the specific recommendations provided in the product’s prescribing information.

Safety data for Normosang in pregnancy and lactation are limited. The product should only be used when the potential benefit to the mother outweighs any possible risk to the fetus or infant. Clinicians should discuss the uncertainties with the patient and consider alternative therapies when appropriate.

To order Normosang, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where required) and necessary import documentation.

The primary alternative to hemin therapy is high‑dose glucose infusion, which can suppress ALAS1 indirectly. Hemin provides a more direct and rapid replenishment of heme, often resulting in faster symptom control. However, glucose therapy may be used when hemin is unavailable or contraindicated, though it generally requires higher doses and longer administration periods.

Normosang should be stored at 2‑8 °C in a refrigerator. Keep the vial in its original packaging, protect it from light, and avoid freezing or shaking the solution. Once removed from refrigeration, use the product within the time frame specified in the label and discard any unused portion.

Normosang is given as an intravenous infusion. The recommended infusion rate and duration are outlined in the prescribing information and should be followed to minimize infusion‑related reactions. Administration is typically performed by a qualified healthcare professional in a setting equipped to manage potential adverse events.

The most serious risks include anaphylactic or severe allergic reactions, hemolysis in patients with glucose‑6‑phosphate dehydrogenase (G6PD) deficiency, and acute renal failure, especially with high‑dose or prolonged treatment. Early recognition and prompt medical intervention are essential to mitigate these potentially life‑threatening complications.

Normosang is contraindicated in patients with known hypersensitivity to human hemin or any excipients in the formulation. It should also be avoided in individuals with confirmed G6PD deficiency due to the risk of hemolysis, and in patients where the risk of severe infusion reactions outweighs the expected therapeutic benefit.